Fusion protein and application thereof

Abstract

The invention relates to the technical field of a biology, and discloses fusion protein and an application thereof. The fusion protein has an amino acid sequence as shown in SEQ ID NO:1, or has an amino acid sequence obtained in such a way that one or more cases of replacement, deletion and addition happens based on the amino acid sequence as shown in SEQ ID NO:1 without causing changing of bioactivity, or has an amino acid sequence obtained after modification based on the amino acid sequence as shown in SEQ ID NO:1. The fusion protein can restrain apoptosis of alveolar epithelial cells, reduce inflammation promoting factor levels of serum and alveolar washing liquid, can increase the inflammation restraining factor level, and can reduce lung inflammation and tissue pathological changes, so that disease progress can be effectively delayed, the effect of disease damage can be reduced, and the fusion protein can be used as a bran-new COPD treatment medicine.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a fusion protein and its application. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a disease in which airflow limitation is not fully reversible, develops progressively, and is related to lung inflammation. COPD primarily affects the lungs, but can also cause systemic adverse effects. The main clinical manifestations are chronic cough, sputum production, shortness of breath or dyspnea, wheezing and chest tightness. As the disease progresses, systemic inflammatory reactions will also occur, seriously affecting the patient's working ability and quality of life. [0003] COPD is a common, multiple, irreversible chronic respiratory disease with high morbidity and mortality. It has become a global and important public health problem. Approximately 600 million people worldwide suffer from COPD, and approximately 2.7 million people die from the disease eac...

AI Technical Summary

Problems solved by technology

In recent years, due to the recognition that COPD is an airway inflammatory disease, glucocorticoids have been widely used in the treatment of COPD. The 2011 GOLD guidelines recommend long-term inhaled glucocorticoids for patients with severe and very severe COPD. and patients with frequent exacerbations whose symptoms are not well controlled by long-acting bronchodilators

However, in actual clinical treatment, compared with the high efficiency of inhaled glucocorticoids for asthma, corticosteroids have limited therapeutic effects on COPD, and even large doses of inhaled glucocorticoids or even oral glucocorticoids cannot slow down the progressive progression of COPD patients. Airflow obstruction, or reduce the expression of various inflammatory cells, cytokines or proteases, only 10% of COPD patients are effective for inhaled glucocorticoids, and many COPD patients have glucocorticoid resistance

[0008] Therefore, the existing methods for treating COPD cannot effectively delay or prevent the recurrence and progressive development of the disease.

Images